Anti-glycation composition for sensitive skin and use thereof

Abstract

The application discloses a glycation-resistant composition suitable for sensitive skin and application thereof and belongs to the technical field of cosmetics. The glycation-resistant composition is prepared by compounding schisandra chinensis extract, oxidized white resveratrol, ascorbic acid polypeptide, recombinant humanized collagen and recombinant elastin, can effectively realize multi-target synergistic effect of the glycation-resistant composition, can inhibit the generation of glycosylation end product AGEs, reduce glycation stress inflammatory damage, supplement skin structure protein loss caused by protein glycation, form a mild and systematic anti-glycation network, has remarkable yellow-removing, lightening, elastic and firming effects on the skin, is mild and non-irritating, and is suitable for long-term use of people with sensitive skin.

Description

Technical Field

[0001] This invention belongs to the field of cosmetic technology, and in particular relates to an anti-glycation composition suitable for sensitive skin and its application. Background Technology

[0002] Glycation refers to a series of complex reactions between reducing sugars and biomolecules such as proteins, lipids, or nucleic acids under non-enzymatic conditions, ultimately forming stable advanced glycation end products (AGEs). In the skin, the accumulation of AGEs cross-links with structural proteins such as collagen and elastin, leading to damage to their structure and function. This manifests as increased fragility of collagen fibers and breakage of elastic fibers, resulting in collagen loss and decreased skin elasticity. Simultaneously, AGEs can activate their receptor (RAGE) pathway, inducing oxidative stress and chronic inflammatory responses, further exacerbating dermal matrix degradation, promoting increased melanin synthesis and disordered keratinocyte metabolism, ultimately leading to multiple signs of aging such as dullness, yellowing, and sagging skin.

[0003] Existing anti-glycation ingredients or technologies mainly include AGEs inhibitors represented by aminoguanidine, anti-glycation agents represented by carnosine, and antioxidants represented by alpha-lipoic acid. Although these ingredients can inhibit the formation of AGEs or block their receptor pathways to a certain extent, they often have limitations in practical applications: for example, aminoguanidine has the risk of cytotoxicity, some peptide ingredients have low transdermal absorption efficiency, and many antioxidant ingredients have poor stability in formulations or may irritate sensitive skin, making it difficult to use them safely for daily care of fragile skin in the long term. Summary of the Invention

[0004] The purpose of this invention is to overcome the shortcomings of the prior art and provide an anti-glycation composition and its application that has a multi-target synergistic effect, can inhibit the generation of advanced glycation end products (AGEs), reduce glycation stress and inflammatory damage, replenish the loss of skin structural proteins caused by protein glycation, form a mild and systematic anti-glycation network, and has a significant effect on brightening, firming and elasticizing the skin. It is also mild and non-irritating and suitable for long-term use by people with sensitive skin.

[0005] To achieve the above objectives, in a first aspect of the present invention, the present invention provides an anti-glycation composition suitable for sensitive skin, the anti-glycation composition comprising the following components: Schisandra chinensis extract, oxidized resveratrol, ascorbic acid peptide, recombinant humanized collagen, and recombinant elastin.

[0006] This invention has discovered that by selecting Schisandra chinensis extract, oxidized resveratrol, ascorbic acid peptides, recombinant humanized collagen, and recombinant elastin for compounding, a multi-target synergistic effect of the anti-glycation composition can be effectively achieved. It can inhibit the generation of advanced glycation end products (AGEs), reduce glycation stress-induced inflammatory damage, and replenish the loss of skin structural proteins caused by protein glycation, forming a gentle and systematic anti-glycation network. It has a significant effect on brightening, firming, and smoothing the skin, and is gentle and non-irritating, making it suitable for long-term use by people with sensitive skin.

[0007] Specifically, the extract of Schisandra chinensis is derived from the Schisandra chinensis plant (of the Magnoliaceae family). Schisandra sphenanthera It is made from the dried, ripe fruit of Schisandra chinensis, and is refined through extraction. It is rich in total schisandrin (such as schisandrin A and schisandrin A), active polypeptides and polysaccharides. Studies have found that Schisandra chinensis extract can exert soothing, anti-inflammatory and skin barrier repair effects by regulating inflammatory signaling pathways such as NF-κB. In addition, based on the antioxidant and cell protection properties of Schisandra chinensis extract, it can also help improve skin firmness and enhance skin tone brightness. Moreover, it is mild and friendly to sensitive skin.

[0008] Oxidized resveratrol is a polyphenolic derivative derived from plants such as mulberry and Japanese knotweed. Its molecular structure is rich in highly active hydroxyl groups, which can effectively scavenge free radicals and inhibit the formation of intermediate products in glycation reactions, thus exerting significant antioxidant and anti-glycation effects.

[0009] Ascorbic acid polypeptide (INCI name: ASCORBIC ACID POLYPEPTIDE, CAS No.: 167973-55-9) is an active ingredient produced by reacting ascorbic acid with protein hydrolysates using biotechnology. It is rich in stable vitamin C and skin-friendly amino acids. It possesses highly effective antioxidant properties, effectively neutralizing free radicals and reducing environmental damage to the skin. Simultaneously, it inhibits tyrosinase activity, thereby reducing melanin synthesis and brightening the skin. Furthermore, it has moisturizing properties, effectively improving skin hydration and reducing irritation.

[0010] Recombinant humanized collagen is produced through genetic engineering, where the gene encoding human collagen is transferred into host cells (such as Escherichia coli, yeast, Arabidopsis thaliana, etc.), followed by fermentation / culture and purification processes. It possesses a triple helix structure highly compatible with the human body, exhibiting excellent biocompatibility and cell adhesion activity, promoting epithelial cell growth. Simultaneously, it replenishes collagen in the skin's basement membrane and dermal matrix, improving skin firmness. Furthermore, it promotes collagen synthesis by fibroblasts, increasing skin fullness and firmness. Moreover, recombinant humanized collagen can, to some extent, combine with ascorbic acid peptides to form a hydrophilic film, enhancing skin hydration and increasing both the penetration and gentleness of anti-glycation compositions.

[0011] Elastin is an important structural protein in the extracellular matrix of the dermal layer of the skin. Recombinant elastin is prepared by transferring the gene encoding elastin into host cells through genetic engineering, followed by fermentation / culture and purification processes. Recombinant elastin can promote cell adhesion and proliferation, thereby improving skin adhesion, promoting the formation of elastic fibers, and effectively enhancing skin elasticity. In particular, when combined with other components such as recombinant humanized collagen, it can further enhance skin elasticity and firmness.

[0012] As a preferred embodiment of the anti-glycation composition of the present invention, the anti-glycation composition comprises the following components in parts by weight: 2-100 parts of Schisandra chinensis extract, 1-50 parts of oxidized resveratrol, 1-50 parts of ascorbic acid peptide, 0.1-20 parts of recombinant humanized collagen, and 0.005-1 parts of recombinant elastin.

[0013] As a preferred embodiment of the anti-glycation composition of the present invention, the anti-glycation composition comprises the following components in parts by weight: 10-80 parts of Schisandra chinensis extract, 5-30 parts of oxidized resveratrol, 5-30 parts of ascorbic acid peptide, 1-8 parts of recombinant humanized collagen, and 0.05-0.4 parts of recombinant elastin.

[0014] As a preferred embodiment of the anti-glycation composition of the present invention, the anti-glycation composition comprises the following components in parts by weight: 30-50 parts of Schisandra chinensis extract, 10-20 parts of oxidized resveratrol, 10-20 parts of ascorbic acid peptide, 2-4 parts of recombinant humanized collagen, and 0.1-0.2 parts of recombinant elastin.

[0015] This invention has found that the mass fraction of components in an anti-glycation composition affects the interactions between components, thereby influencing the synergistic effect of the anti-glycation composition on multiple targets, and consequently affecting the inhibitory effect on the synthesis of advanced glycation end products (AGEs) and the soothing effect on glycation-induced inflammatory damage. It also affects the replenishment of skin structural proteins and the regulation of skin brightness, and further influences the mildness of the anti-glycation composition. When the mass fraction of components in the anti-glycation composition is further selected within the above-mentioned range, especially within a further preferred range, the overall effect of the obtained anti-glycation composition is even better.

[0016] As a preferred embodiment of the anti-glycation composition of the present invention, the recombinant humanized collagen includes at least one of recombinant type I humanized collagen and recombinant type III humanized collagen.

[0017] Preferably, the recombinant humanized collagen contains 40-80% recombinant type I humanized collagen by mass.

[0018] For example, in the recombinant humanized collagen, the mass percentage of recombinant type I humanized collagen can be any point value or any two points between 40% and 80%, such as 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, etc.

[0019] This invention has found that recombinant type I humanized collagen has strong support, providing basal support and enhancing moisturizing effects, and can also brighten the skin by strengthening the skin barrier; recombinant type III humanized collagen has high bioactivity and can effectively tighten the skin; when the recombinant humanized collagen is further selected to include both recombinant type I and recombinant type III humanized collagen, especially when the mass ratio of the two is within the above range, the resulting system has excellent stability and can effectively achieve better skin tightening, skin brightening, and reduced irritation effects simultaneously.

[0020] In a preferred embodiment of the anti-glycation composition of the present invention, the total schisandrin in the Schisandra chinensis extract is 3-16% by mass.

[0021] For example, the total schisandrin mass percentage in the Schisandra chinensis extract can be any point value or any two points between 3% and 16%, such as 3%, 5%, 8%, 10%, 12%, 14%, 16%, etc.

[0022] Preferably, the total schisandrin content in the Schisandra chinensis extract is 10-13% by mass. For example, it can be 10%, 11%, 12%, 13%, etc.

[0023] It should be noted that the mass percentage of total schisandrin in the *Schisandra chinensis* extract is determined by UV-Vis colorimetry, specifically including the following steps: 1. Preparation of standard curve Accurately weigh 3.00 mg of schisandrin B standard, dissolve it in methanol, and dilute to 25 mL to prepare a stock solution. Accurately measure 0.2, 0.4, 0.8, 1.6, and 3.2 mL of this stock solution into a series of test tubes, and evaporate the solvent under vacuum. Add 0.5 mL of freshly prepared 10% chromotropic acid solution, 1.5 mL of deionized water, and 3.0 mL of concentrated sulfuric acid to each test tube sequentially, and mix well. Place the test tubes in a boiling water bath for 30 minutes to carry out the derivatization reaction, and then cool to room temperature. Using a UV-Vis spectrophotometer, with a blank tube as a reference, measure the absorbance of each standard solution at a wavelength of 570 nm. Plot a standard curve with the mass (mg) of schisandrin B as the x-axis and absorbance as the y-axis, and calculate the regression equation. 2. Sample solution preparation and determination Accurately weigh 1.00 mg of sample into a test tube, and process it according to the same steps as the standard curve preparation (adding reagents, derivatization, cooling). Finally, measure its absorbance value at a wavelength of 570 nm. 3. Analysis, quality control and calculation The absorbance of all standards and sample solutions was measured at 570 nm using a UV-Vis spectrophotometer. The measured absorbance values ​​were substituted into the regression equation of the schisandrin standard curve, and the calculated mass (mg) represents the total schisandrin content (mg) in 1.00 mg of the sample. The quality control requirements for this method include: the correlation coefficient of the standard curve must be greater than 0.99, and the relative standard deviation (RSD) of the concentrations calculated from parallel samples should be less than 5.0%.

[0024] It should be noted that the present invention does not particularly limit the preparation method of Schisandra chinensis extract, and conventional extraction methods in the art can be used. Furthermore, the Schisandra chinensis extract in this invention can be prepared using a self-made method or purchased through conventional commercial channels.

[0025] For example, the preparation method of the Schisandra chinensis extract may be ultrasonic extraction, water extraction, alcohol extraction, etc.

[0026] Specifically, the ultrasonic extraction method involves adding Schisandra chinensis powder to methanol for ultrasonic extraction. After ultrasonic extraction, solid-liquid separation is performed, the liquid is collected and dried to obtain Schisandra chinensis extract. For example, the ultrasonic extraction power can be 200±20W, the ultrasonic extraction time can be 30±5min, the ultrasonic extraction temperature can be 50±5℃, and the mass-to-volume ratio of Schisandra chinensis powder to methanol can be 1g:(20-40)mL.

[0027] The water extraction method is as follows: Schisandra chinensis powder is added to pure water and heated for extraction. After extraction, the solid and liquid are separated, the liquid is collected and dried to obtain Schisandra chinensis extract. For example, the water extraction time can be 60±10 min, the water extraction temperature can be 90-100℃, and the mass-volume ratio of Schisandra chinensis powder to pure water can be 1g:(20-40)mL.

[0028] The alcohol extraction method is as follows: Schisandra chinensis powder is added to a methanol-water solution and heated under reflux. After extraction, solid-liquid separation is performed, the liquid is collected and dried to obtain Schisandra chinensis extract. For example, the reflux time can be 30±5 min, the mass-to-volume ratio of Schisandra chinensis powder to methanol-water solution can be 1 g:(20-40) mL, and the mass percentage of methanol in the methanol-water solution is 85-98%.

[0029] This invention has found that the mass percentage of total schisandrin in Schisandra chinensis extract not only affects its antioxidant and anti-inflammatory effects, but also its interaction with other components. When the mass percentage of total schisandrin in Schisandra chinensis extract is further selected to be within the above-mentioned range, the resulting product not only has a better brightening and firming effect, but also has lower irritation.

[0030] As a preferred embodiment of the anti-glycation composition of the present invention, the mass ratio of recombinant humanized collagen to recombinant elastin is recombinant humanized collagen: recombinant elastin = (10-40): 1.

[0031] For example, the mass ratio of recombinant humanized collagen to recombinant elastin can be any point value or any two points between recombinant humanized collagen: recombinant elastin = (10-40):1, such as 10:1, 15:1, 20:1, 25:1, 30:1, 35:1, 40:1, etc.

[0032] Preferably, the mass ratio of recombinant humanized collagen to recombinant elastin is recombinant humanized collagen:recombinant elastin = (15-25):1. For example, it can be 15:1, 18:1, 20:1, 22:1, 25:1, etc.

[0033] This invention has found that the mass ratio of recombinant humanized collagen to recombinant elastin affects the overall performance. When the mass ratio of the two is further selected within the above range, they have a certain synergistic effect and can be better combined with other components, effectively protecting the skin collagen network, increasing the core collagen content of the skin, and enhancing skin firmness. In addition, it can also effectively improve skin hydration and reduce irritation.

[0034] In a second aspect, the present invention provides the use of the anti-glycation composition in the preparation of cosmetics.

[0035] As a preferred embodiment of the application described in this invention, the cosmetic includes any one of toner, lotion, cream, mask, lotion, essential oil, and spray.

[0036] In a third aspect, the present invention provides a face cream comprising the following components by weight percentage: 0.1-1% of the anti-glycation composition of the present invention, 0.1-1% of a thickener, 2-15% of a moisturizer, 5-15% of a skin emollient, 0.5-5% of an emulsifier, 0.01-0.3% of a pH adjuster, 0.1-1% of an antioxidant, and the balance being deionized water.

[0037] As a preferred embodiment of the face cream of the present invention, the thickener includes at least one of the following: polyacrylate crosspolymer-6, carbomer, carrageenan, gellan gum, xanthan gum, microcrystalline cellulose, cellulose gum, ethyl cellulose, arugula gum, guar gum, ammonium acryloyl dimethyl taurate / VP copolymer, acrylate copolymer, sclerotium gum, polyvinylpyrrolidone, amylopectin, and sodium polyacrylate.

[0038] As a preferred embodiment of the face cream of the present invention, the moisturizer includes at least one of glycerin, 1,2-butanediol, 1,4-butanediol, 1,2-hexanediol, 1,3-propanediol, 1,2-pentanediol, butylene glycol, caprylyl glycol, dipropylene glycol, tremella polysaccharide, trehalose, betaine, allantoin, hyaluronic acid, sodium hyaluronate, acetylated sodium hyaluronate, hydrolyzed sodium hyaluronate, sodium hyaluronate crosspolymer, β-glucan, budding stalk polysaccharide, and ceramide.

[0039] In a preferred embodiment of the face cream of the present invention, the emulsifier includes at least one of C14-22 alcohol, C12-20 alkyl glucoside, hydrogenated lecithin, cetearyl glucoside, stearyltrimethylammonium chloride, and cetearyl alcohol.

[0040] In a preferred embodiment of the face cream of the present invention, the emollient includes at least one of caprylic / capric triglyceride, squalane, and shea butter.

[0041] In a preferred embodiment of the face cream of the present invention, the pH adjuster includes at least one of arginine, disodium ethylenediaminetetraacetate, tromethamine, and citric acid.

[0042] In a preferred embodiment of the face cream described in this invention, the antioxidant is p-hydroxyacetophenone.

[0043] Compared with the prior art, the beneficial effects of the present invention are as follows: This invention, through the selection and compounding of Schisandra chinensis extract, oxidized resveratrol, ascorbic acid peptides, recombinant humanized collagen, and recombinant elastin, can effectively achieve the multi-target synergistic effect of the anti-glycation composition. It can inhibit the generation of advanced glycation end products (AGEs), reduce glycation stress-induced inflammatory damage, and replenish the loss of skin structural proteins caused by protein glycation, forming a gentle and systematic anti-glycation network. It has a significant effect on brightening, firming, and smoothing the skin, and is gentle and non-irritating, making it suitable for long-term use by people with sensitive skin. Attached Figure Description

[0044] Figure 1 The comparison chart shows the blank application example in Example 3 and the volunteers in Example 1 before and after using the product. Detailed Implementation

[0045] To better illustrate the purpose, technical solution, and advantages of the present invention, the present invention will be further described below in conjunction with specific embodiments.

[0046] Unless otherwise specified, the reagents, methods and equipment used in this invention are all conventional reagents, methods and equipment in the field; and unless otherwise specified, the raw materials used in parallel experiments are from the same batch.

[0047] Southern Schisandra Powdered Extract 1: Total schisandrin content was 9% by mass, purchased from Draco Natural Products under the trade name Southern Schisandra Powdered Extract; Schisandra chinensis extract 2: The total schisandrin content was 12%, prepared in-house. The preparation method was ultrasonic extraction. Specifically, about 1.0 g of dried Schisandra chinensis powder was accurately weighed, 30 mL of methanol was added, and ultrasonic extraction was performed for 30 minutes. The ultrasonic power was 200 W and the temperature was 50 °C. After extraction, the supernatant was collected by centrifugation and vacuum drying to obtain Schisandra chinensis extract 2. Schisandra chinensis extract 3: The total schisandrin content was 3% by mass. It was prepared in-house by water extraction. Specifically, about 1.0 g of dried Schisandra chinensis powder was accurately weighed, 30 mL of pure water was added, and the mixture was heated to boiling and extracted for 1 hour. The supernatant was collected by centrifugation and then vacuum dried to obtain Schisandra chinensis extract 3. Schisandra chinensis extract 4: The total schisandrin content was 16%, prepared in-house. The preparation method was: heating and reflux extraction. Specifically, about 1.0 g of dried Schisandra chinensis powder was accurately weighed, placed in a 100 mL round-bottom flask, 30 mL of 95% methanol was added, and the mixture was heated and refluxed for 30 minutes. The supernatant was collected by centrifugation and then vacuum dried to obtain Schisandra chinensis extract 4. Oxidized resveratrol: Purchased from Shanghai Maclean Biochemical Technology Co., Ltd., product number O860708; Ascorbic acid peptide: Purchased from BioHarvest Sciences, Canada, under the trade name Myo-Light Peptide C, containing 0.1% ascorbic acid peptide by mass. Recombinant type I humanized collagen: purchased from Shanxi Xukang Biotechnology Co., Ltd., product number xk-250911370-01; Recombinant type III humanized collagen: purchased from Shanxi Xukang Biotechnology Co., Ltd., product number xk-250821-01; Recombinant elastin: Purchased from Guangzhou Jucheng Chemical Co., Ltd., trade name ELA-IFN-100, wherein the mass percentage of recombinant elastin is 1%.

[0048] Recombinant humanized collagen 1: The mass ratio of recombinant type I humanized collagen to recombinant type III humanized collagen is 6:4, that is, the mass percentage of recombinant type I humanized collagen in recombinant humanized collagen 1 is 60%; Recombinant humanized collagen 2: The mass ratio of recombinant type I humanized collagen to recombinant type III humanized collagen is 4:6, that is, the mass percentage of recombinant type I humanized collagen in recombinant humanized collagen 2 is 40%; Recombinant humanized collagen 3: The mass ratio of recombinant type I humanized collagen to recombinant type III humanized collagen is 8:2, that is, the mass percentage of recombinant type I humanized collagen in recombinant humanized collagen 3 is 80%; Recombinant humanized collagen 4: Recombinant type I humanized collagen; Recombinant humanized collagen 5: Recombinant type III humanized collagen.

[0049] Examples 1-7 and Comparative Examples 1-7 The present invention provides an anti-glycation composition in the embodiments and comparative examples, the components (parts by mass) of the anti-glycation composition are shown in Table 1; wherein W represents the mass ratio of recombinant humanized collagen to recombinant elastin; For substances with corresponding brand names, such as ascorbic acid peptides, Table 1 shows the converted parts of the corresponding ascorbic acid peptides in the examples and comparative examples. For example, in Example 1, the ascorbic acid peptides were 15 parts, and the corresponding added myoglobin C was 15,000 parts; the same applies to others. For example, in Example 1, the recombinant elastin was 0.15 parts, and the corresponding added ELA-IFN-100 was 15 parts. Table 1 The method for preparing the anti-glycation composition provided in Example 1 is as follows: the components are mixed evenly to obtain the anti-glycation composition.

[0050] The preparation methods of the anti-glycation compositions provided in Examples 2-7 and Comparative Examples 1-7 are consistent with those in Example 1; if the relevant components are not available, they can be omitted.

[0051] Example 8 This invention provides an anti-glycation composition, the only difference between the anti-glycation composition and Example 1 is that Schisandra chinensis extract 2 is used instead of Schisandra chinensis extract 1.

[0052] Example 9 This invention provides an anti-glycation composition, the only difference between the anti-glycation composition and that of Example 1 is that Schisandra chinensis extract 3 is used instead of Schisandra chinensis extract 1.

[0053] Example 10 This invention provides an anti-glycation composition, the only difference between the anti-glycation composition and that of Example 1 is that Schisandra chinensis extract 4 is used instead of Schisandra chinensis extract 1.

[0054] Example 11 This invention provides an anti-glycation composition, the only difference between the anti-glycation composition and Example 1 is that recombinant humanized collagen 2 is used instead of recombinant humanized collagen 1.

[0055] Example 12 This invention provides an anti-glycation composition, the only difference between the anti-glycation composition and Example 1 is that recombinant humanized collagen 3 is used instead of recombinant humanized collagen 1.

[0056] Example 13 This invention provides an anti-glycation composition, the only difference between the anti-glycation composition and that of Example 1 is that recombinant humanized collagen 4 is used instead of recombinant humanized collagen 1.

[0057] Example 14 This invention provides an anti-glycation composition, the only difference between the anti-glycation composition and that of Example 1 is that recombinant humanized collagen 5 is used instead of recombinant humanized collagen 1.

[0058] Comparative Example 8 The present invention provides an anti-glycation composition in a comparative example. The only difference between the anti-glycation composition and Example 1 is that the Schisandra chinensis extract 1 is replaced with star anise extract (purchased from Xi'an Sosite Biotechnology Co., Ltd., catalog number SOST-CXJ-1210).

[0059] Comparative Example 9 The present invention provides an anti-glycation composition in a comparative example. The only difference between the anti-glycation composition and Example 1 is that resveratrol (purchased from Shanghai Maclean Biochemical Technology Co., Ltd., product number R817263) is used instead of oxidized resveratrol.

[0060] Comparative Example 10 The present invention provides an anti-glycation composition in a comparative example. The only difference between the anti-glycation composition and Example 1 is that soybean peptides (purchased from Shaanxi Yuanzhijin Biotechnology Co., Ltd., catalog number YZJ094) are used instead of ascorbic acid peptides.

[0061] Comparative Example 11 The present invention provides an anti-glycation composition in a comparative example. The only difference between the anti-glycation composition and Example 1 is that bovine bone collagen peptides (purchased from Shanxi Shangnuoda Biotechnology Co., Ltd., catalog number SND-NGJYDBT) are used instead of recombinant humanized collagen 1.

[0062] Comparative Example 12 The present invention provides an anti-glycation composition in a comparative example. The only difference between the anti-glycation composition and Example 1 is that bonito elastin peptide (purchased from Shanxi Blue Whale Biotechnology Co., Ltd., catalog number lj-2025102920) is used instead of recombinant elastin.

[0063] Application examples, comparison application examples, and blank application examples The present invention provides a face cream in application examples, comparative application examples and blank application examples, wherein the mass percentage of the face cream components is shown in Table 2; The antiglycation compositions in Application Examples 1-14 are the antiglycation compositions prepared in Examples 1-14, for example, the antiglycation composition prepared in Example 1 is used in Application Example 1, and so on; the antiglycation compositions in Comparative Application Examples 1-12 are the antiglycation compositions prepared in Comparative Examples 1-12, for example, the antiglycation composition prepared in Comparative Example 1 is used in Comparative Application Example 1, and so on; the antiglycation compositions in Application Examples 15-16 are the antiglycation compositions prepared in Example 1; Table 2 The method for preparing the face cream provided in Example 1 includes the following steps: (1) Mix the humectant and thickener in phase A with water and stir. Heat to 85±2℃ and homogenize at 1200 rpm for 4 min. After homogenization, keep warm for later use to obtain pre-prepared component A. (2) Mix the emollient and emulsifier, heat to 85±2℃, and homogenize at 1200 rpm for 4 min. After homogenization, keep warm for later use to obtain the pre-prepared component B. (3) Mix the antioxidant and humectant in phase C, heat to 60±2℃ to melt, and obtain the pre-prepared phase C; (4) Heat the pre-prepared component A to 80±2℃, add the pre-prepared component B at 250 rpm, stir and mix, then cool down to 60±2℃, add the pre-prepared component C at 250 rpm and stir and mix, then cool down to 40℃, add the anti-glycation composition and continue stirring for 8 min, finally add the pH adjuster to adjust the pH to 6.0, then stop stirring, discharge the material, and obtain the face cream.

[0064] Example 1 The performance of the anti-glycation compositions prepared by the experimental examples and comparative examples of this invention includes the following parts: I. Anti-glycation effect of anti-glycation compositions The test includes the following steps: 1. Preparation of model solution: Bovine serum albumin (BSA, catalog number B824162, Maclean) was dissolved in 0.02 mol / L PBS solution (pH=7.4) to prepare a 25 mg / mL BSA solution. Glucose was added at a glucose to BSA protein ratio of 1:1, and the mixture was thoroughly mixed. The mixture was reacted at 60°C in the dark for 40 h to obtain the model solution for later use. 2. Sample solution preparation: The anti-glycation compositions prepared in the examples and comparative examples were prepared into a 1wt% sample solution using 0.02mol / L PBS solution (pH=7.4) for later use; 3. Test the inhibitory effect of the sample on protein glycation: Prepare the test sample according to the dosage described in Table 3; Table 3 The prepared test sample was reacted in the dark for 1 hour, and the fluorescence was tested. The excitation wavelength was 370 nm and the emission wavelength was 440 nm. The AGEs inhibition rate was calculated according to the following formula, and the results are shown in Table 4. AGEs inhibition rate (%) = [1 - (AB) / (CD)] × 100%; In the formula: A is the fluorescence intensity of the model solution with added sample solution; B is the fluorescence intensity of pure water with added sample solution; C is the fluorescence intensity of the model solution without sample solution; and D is the fluorescence intensity of pure water.

[0065] II. The ability of anti-glycation compositions to resist inflammatory responses caused by protein glycation Advanced glycation end products (AGEs) in the skin can trigger the activation of downstream inflammatory signaling pathways such as NF-κB by activating cell surface receptors (e.g., RAGE), promoting the release of inflammatory factors such as tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6), thereby leading to a persistent low-grade inflammatory state in the skin, exacerbating sensitivity, impaired barrier function, and the aging process. Methylglyoxal (MGO), as one of the key active intermediates of endogenous glycation, can rapidly bind to protein amino groups to form AGEs and strongly induce oxidative stress and inflammatory responses. Therefore, it is often used as a stimulant for establishing in vitro cell models of glycation stress and inflammation. Based on this, this experiment used MGO to stimulate human keratinocytes (HaCaT) to simulate the inflammatory environment induced by glycation. By detecting changes in the level of the core inflammatory factor IL-6 released by the cells, the study evaluated whether the anti-glycation composition could effectively alleviate skin inflammation caused by glycation stress by inhibiting inflammatory pathways, providing cellular-level experimental evidence for its mild anti-glycation efficacy.

[0066] The cell line used was human keratinocytes (HaCaT, Beina Biotechnology). The testing conditions were: incubator temperature 37±1℃, saturated humidity, and carbon dioxide concentration 5±1%. Cells were cultured and treated according to groupings, followed by detection of the inflammatory factor IL-6 content. The testing method is as follows: 1. Seed the cell suspension into a 96-well cell culture plate at a density of 2000 cells / well. Add 100 μL of DMEM high glucose culture medium (product number 2105341, Gibco) containing 10% fetal bovine serum to each well and incubate for 24 h. 2. Discard the supernatant. Add 100 μL of DMEM medium containing 400 μM methylglyoxal (MGO, catalog number H792073, Maclean) to the control group. Add 100 μL of medium containing 1 wt% of the anti-glycation composition prepared in the examples and comparative examples and 400 μM methylglyoxal to the sample groups, respectively. Repeat the process in 6 wells for each group and incubate for 24 h. 3. Detection of inflammatory factor IL-6: The content of inflammatory factor IL-6 released by cells in the culture medium was detected using a human IL-6 ELISA kit (EHC007.96, Shenzhen Xinbosheng Biotechnology Co., Ltd.). The specific procedure was as follows: cells from each group were collected, the supernatant was discarded, and the cells were lysed with RIPA lysis buffer containing protease inhibitors (Shanghai Merck, V900854). The lysed samples were centrifuged at 12000g for 5 minutes, and the supernatant was collected. Then, according to the kit instructions, equal amounts of supernatant were added to the corresponding reaction wells of the kit. After incubation, washing, and color development, the absorbance (OD value) was measured at a specific wavelength using an ELISA reader. The IL-6 content of each group was calculated based on the standard curve.

[0067] The ability of the anti-glycation composition to resist glycation stress-induced inflammatory damage is represented by the improvement in IL-6, calculated as follows: IL-6 improvement rate = (1 - IL-6 content in sample group / IL-6 content in control group) × 100%; The results are shown in Table 4.

[0068] III. The ability of anti-glycation compositions to resist skin aging caused by protein glycation Advanced glycation end products (AGEs) formed during protein glycation can covalently cross-link with collagen and elastin in the dermis, leading to structural rigidity, increased fragility, and difficulty in normal enzymatic renewal. Simultaneously, AGEs can inhibit fibroblast proliferation and function, downregulate the synthesis of type I collagen and elastin, ultimately causing dermal matrix loss and collapse of supporting structures, manifesting as typical aging phenomena such as skin laxity, deepened wrinkles, and decreased elasticity. Based on this mechanism, this experiment treated human dermal fibroblasts with the glycation stressor methylglyoxal (MGO) to simulate the damaging effects of the in vivo glycation microenvironment on key structural proteins. By detecting changes in the content of type I collagen and elastin in cell lysates, the aim was to evaluate whether the proposed composition could effectively alleviate glycation-induced protein loss through mechanisms such as inhibiting AGEs cross-linking, protecting cell function, or promoting matrix synthesis, thereby providing direct cellular efficacy evidence for improving skin structural aging.

[0069] The cell line used was human dermal fibroblast HDF (catalog number PC-202h, Wuhan Saisuo Biotechnology Co., Ltd.). The testing conditions were: incubator temperature 37±1℃, saturated humidity, and carbon dioxide concentration 5±1%. Cells were cultured and treated according to groups, followed by the detection of type I collagen and elastin content. The testing methods are as follows: 1. Seed the cell suspension into a 96-well cell culture plate at a density of 2000 cells / well. Add 100 μL of DMEM high glucose culture medium (product number 2105341, Gibco) containing 10% fetal bovine serum to each well and incubate for 24 h. 2. Discard the supernatant. Add 100 μL of DMEM medium containing 400 μM methylglyoxal (MGO, catalog number H792073, Maclean) to the control group. Add 100 μL of medium containing 1 wt% of the anti-glycation composition prepared in the examples and comparative examples and 400 μM methylglyoxal to the sample groups, respectively. Repeat the process in 6 wells for each group and incubate for 24 h. 3. Type I Collagen Content Detection: The type I collagen content of each group was detected using a human type I collagen (Col I) ELISA kit (catalog number ml057630, Shanghai Enzyme-Linked Biotechnology). The specific procedure was as follows: cells from each group were collected, the supernatant was discarded, and the cells were lysed with RIPA lysis buffer containing protease inhibitors (Shanghai Merck, V900854). The lysed samples were centrifuged at 12000g for 5 minutes, and the supernatant was collected. Then, according to the kit instructions, equal amounts of supernatant were added to the corresponding reaction wells of the kit. After incubation, washing, and color development, the absorbance (OD) value was measured at a specific wavelength using an ELISA reader. The type I collagen content of each group was calculated based on the standard curve. 4. Elastin content detection: The elastin content of each group was detected using a human elastin ELISA kit (catalog number ml038411, Shanghai Enzyme-Linked Biotechnology). The specific procedure was as follows: cells from each group were collected, the supernatant was discarded, and the cells were lysed with RIPA lysis buffer containing protease inhibitors. The lysed samples were centrifuged at 12000g for 5 minutes, and the supernatant was collected. Then, according to the kit instructions, equal amounts of supernatant were added to the corresponding reaction wells of the kit. After incubation, washing, and color development, the absorbance (OD) value was measured at a specific wavelength using an ELISA reader. The elastin content of each group was calculated based on the standard curve. The ability of anti-glycation compositions to combat skin aging caused by glycation is represented by improvements in type I collagen and elastin, calculated as follows: Improvement rate = (OD value sample group - OD value control group) / OD value control group × 100%; The results are shown in Table 4.

[0070] IV. Skin penetration ability of anti-glycation compositions Specifically, the following steps are included: Using ex vivo pig skin testing, the exposed skin area in the diffusion pool was 1.5 cm². 2 The receiving chamber volume was 2.0 mL. Deionized water was used as the receiving solution. 1 mg of each of the anti-glycation compositions prepared in the examples and comparative examples was weighed and added to an appropriate amount of deionized water, mixed thoroughly, and prepared into a total sample solution of 200 μL. Each sample solution was then evenly applied to the skin of the test pigs and covered with a thin film to prevent evaporation. The transdermal absorption M of the protein components was detected using the Bradford method after 24 h. The transdermal absorption rate of the protein components (ascorbic acid peptides, recombinant humanized collagen, and elastin) in the composition was calculated using the following formula: Transdermal absorption rate (%) = M / [mass percentage of protein components in the composition × 200 μL] × 100%; The results are shown in Table 4.

[0071] Table 4 As can be seen from Table 4, when the technical solution provided by the present invention is adopted, the obtained anti-glycation composition has excellent anti-glycation ability, good resistance to glycation and excellent skin permeability; specifically, the obtained anti-glycation composition has an AGEs inhibition rate of more than 56.9%, and in resisting glycation, the IL-6 improvement rate is more than 45.8%, the type I collagen improvement rate is more than 49.3%, the elastin improvement rate is more than 31.7%, and the transdermal absorption rate is more than 53.0%.

[0072] As can be seen from Examples 1-5, the mass fraction of the components affects the interaction between the components, thereby affecting the overall performance of the anti-glycation composition. When the mass fraction of the components is further selected within the preferred range, the AGEs inhibition rate of the obtained anti-glycation composition is above 75.5%. In resisting glycation, the IL-6 improvement rate is above 61.7%, the type I collagen improvement rate is above 67.7%, and the elastin improvement rate is above 43.7%. The transdermal absorption rate is above 77.6%. In Example 4, since the sum of the mass fractions of Schisandra chinensis extract and oxidized resveratrol is significantly less than the sum of the mass fractions of ascorbic acid peptide, recombinant humanized collagen, and recombinant elastin, the compounding effect between the components is relatively poor, and the overall performance obtained is poor in Examples 1-5.

[0073] As can be seen from Examples 1 and 6-7, the mass ratio of recombinant humanized collagen to recombinant elastin also affects the overall performance of the product. When the mass ratio of the two is further selected within the preferred range, the overall performance of the obtained anti-glycation composition is better. As can be seen from Examples 1 and 8-10, the mass percentage of total Schisandra chinensis in the Schisandra chinensis extract also affects the overall performance of the anti-glycation composition to a certain extent. As can be seen from Examples 1 and 11-16, the type of recombinant humanized collagen also affects the overall performance of the anti-glycation composition. When the recombinant humanized collagen is further selected to include both recombinant type I collagen and recombinant type III collagen, and the mass ratio of the two is within the preferred range of the present invention, the overall performance of the obtained anti-glycation composition is better.

[0074] As can be seen from Examples 1 and Comparative Examples 1-7, the overall performance of the anti-glycation compositions significantly decreased when one, two, or three of the ingredients were missing. As can be seen from Examples 1 and Comparative Examples 8-12, the anti-glycation compositions also failed to achieve the desired effects when other similar ingredients were substituted for the ingredients in this invention. However, in Comparative Examples 4-5, since the effect of recombinant humanized collagen or recombinant elastin on transdermal absorption was relatively weak, the transdermal absorption rate of the resulting compositions only showed a slight decreasing trend even without the addition of either of the two. In Comparative Examples 11-12, the effect on transdermal absorption rate was relatively small when other similar substances were substituted for recombinant humanized collagen and recombinant elastin, respectively.

[0075] Example 2 The efficacy examples of this invention explore the irritation properties of the face creams prepared in the application examples, comparative application examples, and blank application examples. Specifically, human patch tests were conducted, including the following: Sixty volunteers were recruited, 30 men and 30 women, aged 20-50 years, and randomly divided into two groups of 15 men and 15 women each. A closed patch assay was used. Equal volumes (0.020 mL-0.025 mL) of test samples (creams prepared for application examples, control examples, and blank examples) were placed in a specific patch applicator. The patch was then applied to the volunteer's arm with hypoallergenic adhesive tape, gently pressed to ensure even application, and left for 24 hours. The blank control group consisted of distilled water. One patch applicator was applied to each arm of each volunteer. Each patch applicator had 10 holes, allowing for the simultaneous testing of 20 samples per volunteer (both arms). The first group used creams prepared for application examples 1-16 and the blank example, while the second group used creams prepared for control examples 1-12 and the blank example. A blank control was included in each group. After 24 hours, remove the patch applicator and observe skin reactions at 0.5 hours, 24 hours, and 48 hours, recording the results. The severity of adverse skin reactions is shown in Table 5 below. Table 5 After testing, the face creams prepared in the application examples, comparative application examples, and blank application examples of this invention all showed negative reactions after human patch testing, indicating that they are safe and non-irritating to human skin.

[0076] Example 3 The performance of the face creams prepared by the present invention's effect examples, comparative application examples, and blank application examples are investigated. The specific test range is as follows: According to the "Cosmetic Safety Technical Specifications" (2015), 174 Asian adults aged 25-60 years with self-reported skin sensitivity were selected for the trial and randomly divided into 29 groups of 6 people each. Volunteers applied the samples (prepared from application examples 1-16, control examples 1-12, and a blank application example) to their entire face twice daily, morning and evening. Data was collected on day 0 (T0) and day 14 (T14). After the trial, volunteers washed their faces with facial cleanser and sat quietly for 30 minutes in an air-conditioned room with a temperature of 21±1℃ and humidity of 50±10%. Researchers used the CK skin color test probe CL400 to measure the yellowness b* value of the cheekbone and the a* value of the cheek using the same probe. A Cutometer (MPA580, Courage and Khazaka, Germany) was used to measure the skin elasticity R2 and firmness F4 of the cheekbone. The skin-brightening effect of the anti-glycation composition is represented by the improvement in yellowness (b*) value; the skin-soothing effect is represented by the improvement in skin (a*) value; the skin-firming effect is represented by the improvement in firmness (F4) value; and the skin-elasticity-increasing effect is represented by the improvement in elasticity parameter (R2) value. The formulas are as follows: b* value improvement rate = (b*) T0 -b* T14 ) / b* T0 ×100%; a* value improvement rate = (a* T0 -a* T14 ) / a* T0 ×100%; F4 value improvement rate = (F4 T0 -F4 T14 ) / F4 T0 ×100%; R² improvement rate = (R²) T14 -R2 T0 ) / R2 T0 ×100%.

[0077] The results are shown in Table 6.

[0078] Table 6 As shown in Table 6, when the technical solution provided by this invention is adopted, the resulting face cream has excellent effects in brightening skin tone, firming skin, and improving skin elasticity, while also exhibiting superior gentleness. Specifically, the obtained face cream improves the human body's b* value by more than 9.5%, a* value by more than 14.0%, F4 value by more than 12.0%, and R2 value by more than 8.8%. The comparison images of volunteers in the blank application example and application example 1 before and after using the corresponding face cream are shown below. Figure 1 As shown, from Figure 1 It is also clear from the example that the face cream obtained by applying Example 1 has excellent overall effects; As can be seen from Application Examples 1-5, the mass fraction of the components in the anti-glycation composition affects the interaction between the components, thereby affecting the overall performance of the prepared face cream. When the mass fraction of the components in the anti-glycation composition is further selected within the preferred range, the resulting face cream improves the human body's b* value by more than 11.8%, a* value by more than 20.2%, F4 value by more than 16.9%, and R2 value by more than 12.3%. As can be seen from Application Examples 1 and Application Examples 6-7, the mass ratio of recombinant humanized collagen to recombinant elastin in the anti-glycation composition also affects the overall performance of the face cream. When the mass fraction of both components is further selected within the preferred range, the overall performance of the face cream is improved. When the mass ratio is within the preferred range, the resulting face cream has better overall performance. As can be seen from Application Examples 1 and 8-10, the mass percentage of total Schisandra chinensis in the Schisandra chinensis extract in the anti-glycation composition also affects the overall performance of the face cream to some extent. As can be seen from Application Examples 1 and 11-16, the type of recombinant humanized collagen in the anti-glycation composition also affects the overall performance of the face cream. When the recombinant humanized collagen in the anti-glycation composition is further selected to include both recombinant type I collagen and recombinant type III collagen, and the mass ratio of the two is within the preferred range of the present invention, the resulting face cream has better overall performance. As can be seen from Application Example 1 and Comparative Application Examples 1-7, when one, two, or three of the anti-glycation compositions are missing, the overall performance of the resulting face creams is significantly reduced. As can be seen from Application Example 1 and Comparative Application Examples 8-12, when other similar ingredients are used to replace the ingredients in this invention, the resulting face creams also fail to achieve the effects of this invention.

[0079] Finally, it should be noted that the above embodiments are used to illustrate the technical solutions of the present invention and not to limit the scope of protection of the present invention. Although the present invention has been described in detail with reference to preferred embodiments, those skilled in the art should understand that modifications or equivalent substitutions can be made to the technical solutions of the present invention without departing from the essence and scope of the technical solutions of the present invention.

Claims

1. An anti-glycation composition suitable for sensitive skin, characterized in that, The anti-glycation composition comprises the following components: Schisandra chinensis extract, oxidized resveratrol, ascorbic acid peptide, recombinant humanized collagen, and recombinant elastin.

2. The anti-glycation composition according to claim 1, characterized in that, The anti-glycation composition comprises the following components in parts by weight: 2-100 parts Schisandra chinensis extract, 1-50 parts resveratrol oxide, 1-50 parts ascorbic acid peptide, 0.1-20 parts recombinant humanized collagen, and 0.005-1 part recombinant elastin.

3. The anti-glycation composition according to claim 2, characterized in that, The anti-glycation composition comprises the following components in parts by weight: 10-80 parts Schisandra chinensis extract, 5-30 parts oxidized resveratrol, 5-30 parts ascorbic acid peptide, 1-8 parts recombinant humanized collagen, and 0.05-0.4 parts recombinant elastin.

4. The anti-glycation composition according to claim 3, characterized in that, The anti-glycation composition comprises the following components in parts by weight: 30-50 parts Schisandra chinensis extract, 10-20 parts resveratrol oxide, 10-20 parts ascorbic acid peptide, 2-4 parts recombinant humanized collagen, and 0.1-0.2 parts recombinant elastin.

5. The anti-glycation composition according to claim 1, characterized in that, The recombinant humanized collagen includes at least one of recombinant type I humanized collagen and recombinant type III humanized collagen.

6. The anti-glycation composition according to claim 5, characterized in that, The recombinant humanized collagen contains 40-80% recombinant type I humanized collagen by mass.

7. The anti-glycation composition according to claim 1, characterized in that, The total schisandrin content in the *Schisandra chinensis* extract is 3-16% by mass.

8. The anti-glycation composition according to claim 1, characterized in that, The mass ratio of recombinant humanized collagen to recombinant elastin is recombinant humanized collagen: recombinant elastin = (10-40):

1.

9. The use of the anti-glycation composition according to any one of claims 1-8 in the preparation of cosmetics.

10. A face cream, characterized in that, The face cream comprises the following components by weight percentage: 0.1-1% of the anti-glycation composition as described in any one of claims 1-8, 0.1-1% of thickener, 2-15% of moisturizer, 5-15% of emollient, 0.5-5% of emulsifier, 0.01-0.3% of pH adjuster, 0.1-1% of antioxidant, and the balance being deionized water.

Images